Zobrazeno 1 - 10
of 44
pro vyhledávání: '"R Forcignanò"'
Autor:
Giovanni Bozza, Sante Romito, Salvatore Pisconti, Mariangela Ciccarese, Paola Schiavone, Palma Fedele, Michele Aieta, Giuseppe Colucci, Goim, Giammarco Surico, Saverio Cinieri, Laura Orlando, R. Forcignanò, Vito Lorusso, Evaristo Maiello, Valeria Saracino, Antonio Febbraro, Ferdinando Riccardi, Roberto Bordonaro, Antonio Rinaldi, Nicolò Borsellino, Giuseppina Cilenti
Publikováno v:
The Breast Journal. 26:1857-1859
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5ecfa3ece299999a58e188aae14a4a
https://doi.org/10.1111/tbj.13856
https://doi.org/10.1111/tbj.13856
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marina Elena Cazzaniga, Mariangela Ciccarese, L. Lupo, A Cusmai, A. Fabi, Domenico Bilancia, Francesco Giotta, Gennaro Palmiotti, L. Petrucelli, Marianna Giampaglia, Assunta Tornesello, Guido Giordano, E. De Matteis, R. Forcignanò, Evaristo Maiello, G. Cairo, N La Verde, Vincenzo Emanuele Chiuri, Maria Morritti, Sante Romito, Claudio Scavelli, S Campidoglio, Vito Lorusso, Antonio Febbraro
Publikováno v:
Cancer Research. 76:P4-13
BACKGROUND: Everolimus, an mTOR inhibitor, in combination with exemestane is approved for hormone receptor (HR) positive advanced breast cancer (ABC), after failure of treatment with non-steroidal aromatase inhibitor (NSAI). We assessed the toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd2050f6965f600ca1d36eff02317196
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-15
https://doi.org/10.1158/1538-7445.sabcs15-p4-13-15
Autor:
M. De Giorgio, Silvana Leo, G. Ronzino, S. Mauro, L. Palma, G. Cairo, R. Forcignanò, I. Bovenga, E. Spro, E. De Matteis, Mariangela Ciccarese, Vincenzo Emanuele Chiuri, Paolo Tarantino
Publikováno v:
European Journal of Cancer. 138:S79
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83781ba908a2a1cb8bbcaeff7ac66da5
https://doi.org/10.1016/s0959-8049(20)30741-3
https://doi.org/10.1016/s0959-8049(20)30741-3
Autor:
E. Quarta, D. Ciardo, Fiorella Anna Lombardi, Antonella Grimaldi, R. Forcignanò, M. Ciccarese, M. Di Paola, Sergio Casciaro, Paola Pisani, Maurizio Muratore, Francesco Conversano
Publikováno v:
Annals of the Rheumatic Diseases. 79:1187.2-1188
Background:Aromatase inhibitor (AI) therapy in women with estrogen receptor-positive (ER+) breast cancer (BC) causes accelerated bone loss and increased risk of osteoporosis and fractures as side effects. Denosumab (i.e. 60 mg twice a year) is a viab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37faac27141ef2890be9d42171cc906e
https://doi.org/10.1136/annrheumdis-2020-eular.3806
https://doi.org/10.1136/annrheumdis-2020-eular.3806
Autor:
Laura Mercatali, Chiara Spadazzi, Manuela Fantini, Valentina Fausti, Jessica Menis, Francesco Silvestris, Giandomenico Di Menna, Roberto Vespignani, Toni Ibrahim, Rossana Berardi, R. Forcignanò, Flavia Foca, Silvia Angela Debonis, Federica Recine, Banca Dati Metastasi Ossee Study Team, Nada Riva, Giuseppe Procopio, Alberto Bongiovanni, Fabrizio Artioli, Enrico Campadelli, Lorena Gurrieri
Publikováno v:
Journal of Clinical Oncology. 38:e13072-e13072
e13072 Background: Bone Metastases (BM) are still the main cause of morbidity and morbility in cancer patients because of their complications defined as skeletal-related events (SREs).SREs reduce pts quality of life and are associated with an increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aba44c845eafc62cd360e62b288d8936
https://doi.org/10.1200/jco.2020.38.15_suppl.e13072
https://doi.org/10.1200/jco.2020.38.15_suppl.e13072
Autor:
E. Quarta, M. Ciccarese, Francesco Conversano, Maurizio Muratore, M. Di Paola, Giammarco Surico, R Tarparelli, Ernesto Casciaro, D. Costanza, Paola Pisani, R. Franchini, R. Forcignanò, L. Quarta, Sergio Casciaro
Publikováno v:
Poster Presentations.
Background The Aromatase Inhibitors (AIs)-based therapy used in breast cancer patients to profoundly lower estrogen levels seems to enhance the loss of bone mineral density (BMD) and to increase the fragility fracture rate [1]. Several clinical studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02fe1c66d98bf6a7e3ebeef6e41933f0
https://doi.org/10.1136/annrheumdis-2017-eular.4060
https://doi.org/10.1136/annrheumdis-2017-eular.4060
Autor:
Maria Elena Cazzaniga, Nicla La Verde, Vincenzo Emanuele Chiuri, Marianna Giampaglia, Domenico Bilancia, Alessandra Fabi, Mariangela Ciccarese, A Latorre, Antonio Cusmai, Antonio Febbraro, Luca Moscetti, Evaristo Maiello, L. Petrucelli, L. Lupo, Francesco Giotta, Gennaro Palmiotti, Guido Giordano, Claudio Scavelli, Vito Lorusso, Sante Romito, Elisabetta De Matteis, Giammarco Surico, Maria Morritti, G. Cairo, R. Forcignanò
Publikováno v:
Breast cancer research and treatment. 163(3)
Aim: This retrospective analysis focused on the effect of treatment with EVE/EXE in a real-world population outside of clinical trials. We examined the efficacy of this combination in terms of PFS and RR related to dose intensity (5 mg daily versus 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de30ed0398a92b1934a3ce95eb47bc77
https://pubmed.ncbi.nlm.nih.gov/28353061
https://pubmed.ncbi.nlm.nih.gov/28353061
Autor:
G. Cairo, Vincenzo Emanuele Chiuri, V. Saracino, Mariangela Ciccarese, Diana Giannarelli, A. Licchetta, R Forcignanò, L. Lupo, A Gambino, A. Fabi, L Petrucelli, G. Ronzino
Publikováno v:
Cancer Research. 73:P6-10
Background: MBC remains an incurable disease with a median survival of 2-3 years despite the use of new drugs. The validation of PPS as surrogate endpoint and its correlation to PFS and OS is matter of debate. Methods: From 2006-2012 we analyzed retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7748cf7fbf70ea3156f08c41b6d548c
https://doi.org/10.1158/0008-5472.sabcs13-p6-10-01
https://doi.org/10.1158/0008-5472.sabcs13-p6-10-01
Autor:
Andrea Tinelli, Anna Elisa Quatrale, R. Forcignanò, Letizia Porcelli, Vincenzo Emanuele Chiuri, Vito Lorusso, Saverio Cinieri
Publikováno v:
Scopus-Elsevier
EGFR and HER2 are highly expressed in 15-30% of breast cancer tissues. Therefore, EGFR and its downstream signaling pathways are promising anti-tumour targets. HER2 overexpression is often associated with estrogen receptor (ER) and progesterone recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03bf1904a18f4263c0b5b569c3f19e72
https://doi.org/10.2741/s249
https://doi.org/10.2741/s249